{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T19:14:11Z","timestamp":1777058051182,"version":"3.51.4"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T00:00:00Z","timestamp":1656028800000},"content-version":"vor","delay-in-days":174,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pathology Informatics"],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/j.jpi.2022.100116","type":"journal-article","created":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T01:45:24Z","timestamp":1656985524000},"page":"100116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Computer-aided scoring of erb-b2 receptor tyrosine kinase 2 (HER2) gene amplification status in breast cancer"],"prefix":"10.1016","volume":"13","author":[{"given":"Alyson","family":"Yoder","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Landon J.","family":"Inge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen-Chun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijay R.","family":"Marati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trung Kien","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karel","family":"Zuiderveld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jim","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Gladden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Saleh","family":"Miri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raghavan","family":"Venugopal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jim","family":"Ranger-Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Guetter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpi.2022.100116_bb0005","author":"Global Cancer Observatory"},{"key":"10.1016\/j.jpi.2022.100116_bb0010","first-page":"169","article-title":"Assessment of HER2 testing patterns, HER2+ disease, and the utilization of HER2-directed therapy in early breast cancer","volume":"6","author":"Stenehjem","year":"2014","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"10.1016\/j.jpi.2022.100116_bb0015","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1186\/1471-2407-13-615","article-title":"Assessment of HER2 status in breast cancer: overall positivity rate and accuracy by fluorescence in situ hybridization and immunohistochemistry in a single institution over 12 years: a quality control study","volume":"13","author":"Varga","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jpi.2022.100116_bb0020","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.jpi.2022.100116_bb0025","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1200\/JCO.1989.7.8.1120","article-title":"HER-2\/neu oncogene protein and prognosis in breast cancer","volume":"7","author":"Tandon","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jpi.2022.100116_bb0030","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0140-6736(16)32616-2","article-title":"Herceptin Adjuvant Trial Study T. 11 years\u2019 follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial","volume":"389","author":"Cameron","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jpi.2022.100116_bb0035","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3816\/CBC.2010.n.037","article-title":"Effect of trastuzumab on health-related quality of life in patients with HER2-positive metastatic breast cancer: data from three clinical trials","volume":"10","author":"Rugo","year":"2010","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.jpi.2022.100116_bb0040","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"human epidermal growth factor receptor 2 testing in breast Cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jpi.2022.100116_bb0045","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.humpath.2004.01.002","article-title":"Accuracy and precision in HER2\/neu testing in breast cancer: are we there yet?","volume":"35","author":"Yaziji","year":"2004","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jpi.2022.100116_bb0050","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.4337","article-title":"Trends in the US and Canadian pathologist workforces from 2007 to 2017","volume":"2","author":"Metter","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jpi.2022.100116_bb0055","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4103\/2153-3539.112689","article-title":"The history of pathology informatics: a global perspective","volume":"4","author":"Park","year":"2013","journal-title":"J Pathol Inform"},{"key":"10.1016\/j.jpi.2022.100116_bb0060","author":"Wilson"},{"key":"10.1016\/j.jpi.2022.100116_bb0065","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1746-1596-8-17","article-title":"Validation of a new classifier for the automated analysis of the human epidermal growth factor receptor 2 (HER2) gene amplification in breast cancer specimens","volume":"8","author":"Furrer","year":"2013","journal-title":"Diagn Pathol"},{"key":"10.1016\/j.jpi.2022.100116_bb0070","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1136\/jcp.2007.048991","article-title":"A public-domain image processing tool for automated quantification of fluorescence in situ hybridisation signals","volume":"61","author":"Konsti","year":"2008","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.jpi.2022.100116_bb0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0123201","article-title":"Fully automated fluorescent in situ hybridization (FISH) staining and digital analysis of HER2 in breast cancer: a validation study","volume":"10","author":"van der Logt","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jpi.2022.100116_bb0080","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s12253-016-0091-4","article-title":"Agreement of different methods for tissue based detection of HER2 signal in invasive breast cancer","volume":"23","author":"Thakral","year":"2017","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.jpi.2022.100116_bb0085","series-title":"VENTANA HER2 Dual ISH DNA Probe Cocktail Interpretation Guide for Breast Carcinoma","author":"Ventana Medical Systems","year":"2019"},{"key":"10.1016\/j.jpi.2022.100116_bb0090","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/modpathol.2016.175","article-title":"\u201cNon-classical\u201d HER2 FISH results in breast cancer: a multi-institutional study","volume":"30","author":"Ballard","year":"2017","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jpi.2022.100116_bb0095","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1200\/JCO.2016.66.6693","article-title":"HER2 gene amplification testing by Fluorescent In Situ Hybridization (FISH): comparison of the ASCO-College of American Pathologists Guidelines with FISH scores used for enrollment in Breast Cancer International Research Group clinical trials","volume":"34","author":"Press","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jpi.2022.100116_bb0100","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.5858\/arpa.2016-0009-OA","article-title":"Assessing the New American Society of Clinical Oncology\/College of American Pathologists guidelines for HER2 testing by fluorescence in situ hybridization: experience of an academic consultation practice","volume":"140","author":"Press","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jpi.2022.100116_bb0105","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1200\/JCO.2015.61.8983","volume":"34","author":"Shah","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jpi.2022.100116_bb0110","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1038\/modpathol.2015.112","article-title":"Impact of updated HER2 testing guidelines in breast cancer--re-evaluation of HERA trial fluorescence in situ hybridization data","volume":"28","author":"Stoss","year":"2015","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jpi.2022.100116_bb0115","series-title":"VENTANA HER2 Dual ISH DNA Probe Cocktail PMA P190031 approval letter, July 28","author":"Center for Devices and Radiological Heath of the Food and Drug Administration","year":"2020"},{"key":"10.1016\/j.jpi.2022.100116_bb0120","article-title":"Automatic quantification of HER2 gene amplification in invasive breast cancer from chromogenic in situ hybridization whole slide images","volume":"6","author":"Hossain","year":"2019","journal-title":"J Med Imaging (Bellingham)"},{"key":"10.1016\/j.jpi.2022.100116_bb0125","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/path.5662","article-title":"Independent real-world application of a clinical-grade automated prostate cancer detection system","volume":"254","author":"da Silva","year":"2021","journal-title":"J Pathol"},{"key":"10.1016\/j.jpi.2022.100116_bb0130","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1200\/JCO.2006.09.2775","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer","volume":"25","author":"Wolff","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jpi.2022.100116_bb0135","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jpi.2022.100116_bb0140","doi-asserted-by":"crossref","DOI":"10.1038\/s41379-021-00813-x","article-title":"HER2 in situ hybridization test in breast cancer: quantifying margins of error and genetic heterogeneity","author":"Pol\u00f3nia","year":"2021","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jpi.2022.100116_bb0145","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/his.13208","article-title":"Counting invasive breast cancer cells in the HER2 silver in-situ hybridization test: how many cells are enough?","volume":"71","author":"Pol\u00f3nia","year":"2017","journal-title":"Histopathology"},{"key":"10.1016\/j.jpi.2022.100116_bb0150","doi-asserted-by":"crossref","first-page":"6404","DOI":"10.1158\/1078-0432.CCR-06-3022","article-title":"Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification","volume":"13","author":"Arnould","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jpi.2022.100116_bb0155","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/sj.bjc.6605939","article-title":"Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer","volume":"103","author":"Guiu","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jpi.2022.100116_bb0160","doi-asserted-by":"crossref","first-page":"R73","DOI":"10.1186\/bcr3690","article-title":"Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study","volume":"16","author":"Schneeweiss","year":"2014","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.jpi.2022.100116_bb0165","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.ejca.2006.11.019","article-title":"Phosphorylated HER-2 tyrosine kinase and Her-2\/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC)","volume":"43","author":"Giuliani","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jpi.2022.100116_bb0170","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1200\/JCO.2019.37.15_suppl.502","article-title":"HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: results from a prospective clinical trial","volume":"37","author":"Filho","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jpi.2022.100116_bb0175","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1136\/jclinpath-2011-200265","article-title":"HER2 genetic heterogeneity in breast carcinoma","volume":"64","author":"Ohlschlegel","year":"2011","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.jpi.2022.100116_bb0180","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/modpathol.2012.36","article-title":"Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance","volume":"25","author":"Seol","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jpi.2022.100116_bb0185","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1309\/AJCP0EN6AQMWETZZ","article-title":"Heterogeneous HER2 gene amplification: impact on patient outcome and a clinically relevant definition","volume":"136","author":"Bartlett","year":"2011","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jpi.2022.100116_bb0190","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/modpathol.2011.206","article-title":"\u201cGenetic heterogeneity\u201d in HER2\/neu testing by fluorescence in situ hybridization: a study of 2,522 cases","volume":"25","author":"Chang","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jpi.2022.100116_bb0195","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/modpathol.2013.103","article-title":"HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity","volume":"27","author":"Hanna","year":"2014","journal-title":"Mod Pathol"}],"container-title":["Journal of Pathology Informatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2153353922007106?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2153353922007106?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:44:05Z","timestamp":1761871445000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2153353922007106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":39,"alternative-id":["S2153353922007106"],"URL":"https:\/\/doi.org\/10.1016\/j.jpi.2022.100116","relation":{},"ISSN":["2153-3539"],"issn-type":[{"value":"2153-3539","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Computer-aided scoring of erb-b2 receptor tyrosine kinase 2 (HER2) gene amplification status in breast cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Pathology Informatics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpi.2022.100116","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Inc. on behalf of Association for Pathology Informatics.","name":"copyright","label":"Copyright"}],"article-number":"100116"}}